City
Epaper

Jaishankar welcomes WHO's decision to grant Emergency Use Listing to Covaxin

By ANI | Updated: November 3, 2021 19:35 IST

External Affairs Minister Dr S Jaishankar on Wednesday welcomed the World Health Organisation (WHO)'s decision to grant approval for Emergency Use Listing (EUL) for Hyderabad-based Bharat Biotech's COVID-19 vaccine, Covaxin.

Open in App

External Affairs Minister Dr S Jaishankar on Wednesday welcomed the World Health Organisation (WHO)'s decision to grant approval for Emergency Use Listing (EUL) for Hyderabad-based Bharat Biotech's COVID-19 vaccine, Covaxin.

"Welcome @WHO's decision to grant Emergency Use Listing to #COVAXIN. It facilitates travel for many Indian citizens and contributes to vaccine equity. Also a global recognition to PM @narendramodi's vision of an #AtmanirbharBharat. A Happier Diwali," Jaishankar tweeted.

The World Health Organization (WHO) has issued an emergency use listing for India's indigenous vaccine Covaxin, adding to a growing portfolio of vaccines validated by WHO for prevention of COVID-19.

The WHO said in a tweet that the Technical Advisory Group, convened by World Health Organisation (WHO), has determined that the Hyderabad-based Bharat Biotech's COVID-19 vaccine meets WHO standards for protection against COVID-19.

"WHO has granted emergency use listing (EUL) to COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19," WHO said in a tweet.

"The Technical Advisory Group, convened by WHO and made up of regulatory experts from around the world, has determined that the Covaxin vaccine meets WHO standards for protection against #COVID19, that the benefit of the vaccine far outweighs risks and the vaccine can be used," it added.

The global health body said that the Covaxin vaccine was also reviewed by WHO's Strategic Advisory Group of Experts on Immunization (SAGE), and recommended the use of this vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above.

"Available data on vaccination of pregnant women with the Covaxin vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned, including a pregnancy sub-study and a pregnancy registry," WHO said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Bharat Biotech InternationalDr s jaishankarWorld Health OrganisationBharat biotech limitedBharat biotech international ltdBharat biotech companyBharat biotech internationalBharat biotech biotech
Open in App

Related Stories

Navi MumbaiNavi Mumbai: NMMC Launches Awareness Drive on World TB Day, Maharashtra Reports 10% of India's Cases

OpinionsMerchants of Death Infiltrate Hospitals

HealthWorld Mental Health Day 2024: Depression and Anxiety Cost 12 Billion Workdays Each Year, Says WHO

NationalBangladesh Crisis: Government Calls All-Party Meeting at 10 AM Today; EAM Dr S Jaishankar to Brief

NationalBird Flu: WHO Confirms Second Avian Influenza A(H9N2) Case in India, Detected in West Bengal

International Realted Stories

International"Australian community grieves with India": MP Mathew Hilakari on Pahalgam attack

InternationalWagah-Attari border closure leaves several families in limbo

InternationalTibetans-in-exile mark 36th birthday of Panchen Lama, pay tribute to Pahalgam terror attack victims

InternationalPakistan: Concerns raised over forced disappearance of student in Karachi

InternationalPolice aircraft crashes in Thailand, killing six